Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Serum Thioredoxin-1 As A Diagnostic Marker For Malignant Peritoneal Mesothelioma

C. Tabata, T. Terada, Rie Tabata, S. Yamada, R. Eguchi, Y. Fujimori, T. Nakano
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Background: Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive malignant tumor of mesothelial origin that shows a limited response to cytoreductive surgery along with intraperitoneal chemotherapy. Therefore, diagnosing DMPM early is very important. Reactive oxygen species play an important role in asbestos toxicity, which is associated with the pathogenesis of DMPM growth. Thioredoxin-1 (TRX) is a small redox-active protein that demonstrates antioxidative activity associated with tumor growth. Here, we investigated the serum levels of TRX in patients with DMPM and compared them with those of a population that had been exposed to asbestos but did not have DMPM. Study: The serum concentrations of TRX were measured in 15 DMPM patients and 34 individuals with benign asbestos-related diseases. Results: We demonstrated that the patients with DMPM had significantly higher serum levels of TRX than the population that had been exposed to asbestos but did not have DMPM. Conclusions: Our data suggest that serum TRX concentration is a useful serum marker for DMPM.
This paper references
The thioredoxin system in cancer.
Elias S. J. Arnér (2006)
Redox regulation of cellular activation.
H. Nakamura (1997)
Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage.
Y. Takagi (1999)
Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection.
Y. Sumida (2000)
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research
D. Baratti (2011)
Latency of asbestos disease among insulation workers in the United States and Canada
I. Selikoff (1980)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
T. Yan (2009)
ATL‐derived factor (ADF), an IL‐2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol‐reduction in the IL‐2 receptor induction.
Y. Tagaya (1989)
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
Advances in malignant mesothelioma.
B. Robinson (2005)
Is Serum Thioredoxin-1 a Useful Clinical Marker for Malignant Pleural Mesothelioma?
R. Maeda (2011)
Consensus statement on peritoneal mesothelioma
M. Deraco (2008)
Epidemiology of peritoneal mesothelioma: a review.
P. Boffetta (2007)
Identification of interleukin 1 alpha produced by the 3B6 human EBV-B cell line.
J. Bertoglio (1989)
Malignant peritoneal mesothelioma: a multicenter study on 81 cases.
V. Manzini (2010)
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
Occupational, domestic and environmental mesothelioma risks in the British population: a case–control study
C. Rake (2009)
Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung.
J. Park (2006)
Transplacental carcinogenesis by stilbestrol.
J. Folkman (1971)
Up‐regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma
K. Kahlos (2001)
The molecular basis of asbestos induced lung injury
D. Kamp (1999)
Tumor angiogenesis: therapeutic implications.
J. Folkman (1971)
Redox imbalance and its control in HIV infection.
H. Nakamura (2002)
Advances in malignant mesothelio
BW Robinson (2005)
Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury.
T. Hoshino (2003)
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues
H. Kim (2004)
Differential gene expression in mesothelioma
B. Rihn (2000)
Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma.
Y. Soini (2001)
Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?
R. Maeda (2011)

This paper is referenced by
Malignant pleural mesothelioma : novel biomarkers and related pathways
Filip Mundt (2013)
Cytoreductive surgical treatment of pleural mesothelioma
M. Costa (2012)
Serum HMGB1 as a Diagnostic Marker for Malignant Peritoneal Mesothelioma
C. Tabata (2013)
Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study
J. Xu (2015)
Preventing recurrence of diffuse malignant peritoneal mesothelioma
Joshua C. Leinwand (2016)
Accurate diagnosis of mesothelioma: more important than ever.
T. Allen (2013)
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
The levels of HDAC1 and thioredoxin1 are related to the death of mesothelioma cells by suberoylanilide hydroxamic acid.
B. You (2016)
Cell Signaling and Epigenetic Mechanisms in Mesothelioma
B. Mossman (2017)
PX-12 inhibits the growth of hepatocelluar carcinoma by inducing S-phase arrest, ROS-dependent apoptosis and enhances 5-FU cytotoxicity.
Guang-zhen Li (2015)
Oxidative stress in diffuse large B-cell lymphoma and follicular lymphoma, and TP53 mutations and translocations of MYC, Bcl-2 and Bcl-6 in diffuse large B-cell lymphoma
P. Peroja (2018)
Peritoneal mesothelioma: current status and future directions.
T. Chua (2012)
Malignant mesothelioma as an oxidative stress-induced cancer: An update.
S. H. Chew (2015)
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.
B. Mossman (2013)
Semantic Scholar Logo Some data provided by SemanticScholar